ipilimumab,nivolumab,relatlimab
bms
['check,mate,067', 'relativity-047']
nice relativity-047 subgroup analysis at #asco22 from . confirms efficacy fairly consistent across key subgroups. included my comparison of some of key prognostic factors vs checkmate-067 fwiw. prognostics reasonably balanced across both trials. 
Biotech Buyside. Tweets are only opinion/speculation and not advice/solicitation. May be L/S names, consider conflicts.